Neurosoft Bioelectronics advances brain interface technology for epilepsy and tinnitus

Geneva-based Neurosoft Bioelectronics has set a new benchmark in neurotechnology with its high-resolution, stretchable brain interface for epilepsy monitoring. The EPFL spin-off successfully tested its device on two human patients, paving the way for broader clinical applications.

Neurosoft Bioelectronics, a neurotechnology start-up specializing in soft, minimally invasive brain interfaces, has achieved a significant milestone in epilepsy treatment. The company recently conducted a world-record-setting trial of its 64-channel stretchable brain interface, offering unprecedented precision in identifying epileptic tissue. The study, held at the University Medical Center (UMC) Utrecht, represents a step forward in developing more effective epilepsy monitoring tools.

The soft, stretchable nature of the device—1,000 to 100,000 times softer than traditional electrodes—allows it to conform more closely to the brain’s surface, improving neural signal detection while minimizing risks associated with invasive surgery. This high-resolution interface enhances surgeons’ ability to differentiate between healthy and epileptic tissue, reducing the likelihood of excessive or insufficient tissue removal.

The feasibility study began in Houston, involving four patients, before the pivotal Utrecht trial led by Professor Maeike Zijlmans. “The flexibility of the Neurosoft grid is particularly useful for detecting small epileptic activity, such as high-frequency oscillations, and refining surgical borders after initial tissue resection,” she explains. Following this success, Neurosoft is preparing for a larger 12-patient study at UMC Utrecht to support regulatory approval and clinical adoption across Europe.

Beyond epilepsy, Neurosoft is advancing its Brain-Computer Interface (BCI) technology to treat severe tinnitus—a condition affecting over 120 million people worldwide. A proof-of-concept clinical study, conducted in partnership with EPFL and the Wyss Center, demonstrated a 28-point reduction in tinnitus severity—130% more effective than current treatments.

Based at the Campus Biotech in Geneva and with ongoing funding from the EIC Accelerator, SERI, and private investors, Neurosoft Bioelectronics is poised to transform neurological care, reinforcing Switzerland’s role at the forefront of brain-interface innovation.